Desheh joined Teva as CFO in 2008 and briefly served as acting CEO from October 2013 to February 2014.
Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps.A string of costly acquisitions, along with delayed drug launches, have sent Teva shares plummeting and led to calls for management and structural changes, including a possible split into separate generic and branded medicine units.Officials at Teva declined to comment on the reports."Hapoalim is now considering the selection of a new chairman for Isracard," Israel's biggest bank said in a statement, noting there were a number of candidates."The selection of a chairman will be subject to the recommendation of Bank Hapoalim's board of directors and the decision of Isracard's board."The appointment would also need approval from the Bank of Israel."When a decision is made, we will announce it to the public," Hapoalim said. (Reporting by Tova Cohen; Editing by Adrian Croft)